Key result
The CRT-REALITY trial is a planned randomized controlled study designed to evaluate whether CRT-D provides a clinical benefit over CRT-P in patients with non-ischemic heart failure without mid-wall fibrosis.
Why the study?
Does CRT-D reduce re-hospitalization for heart failure, ventricular tachycardia, and MACE compared to CRT-P in patients with non-ischemic heart failure, LVEF ≤35%, and no significant mid-wall fibrosis on CMR?
RCT (n=600)
Double-blind
1:1
Yes
Does CRT-D reduce re-hospitalization for heart failure, ventricular tachycardia, and MACE compared to CRT-P in patients with non-ischemic heart failure, LVEF ≤35%, and no significant mid-wall fibrosis on CMR?
The CRT-REALITY study is a randomized controlled trial designed to evaluate whether CRT-D provides additional benefit over CRT-P in patients with non-ischemic heart failure and no significant mid-wall fibrosis on CMR.
Answers are grounded in this paper and cite their sources.
CRT-D benefit over CRT-P remains untested in this population; the planned RCT will deliver the first direct evidence.
BACKGROUND: Primary preventive implantation of implantable defibrillator (ICD) is according to current guidelines indicated in patients with heart failure NYHA (New York Heart Association) class II/III and LVEF <35%. Thanks to advances in heart failure pharmacotherapy, a decrease in mortality could render a benefit of ICD insufficient to justify its implantation in some patients. METHODS: Study design: multicenter, prospective, randomized, controlled trial evaluating the benefit of implantation of Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in non-ischemic patients with reduced left ventricle ejection fraction (LVEF) and optimal pharmacotherapy without significant mid-wall myocardial fibrosis detected by cardiac magnetic resonance (CMR). The primary end-point: Re-hospitalization for heart failure, ventricular tachycardia, major adverse cardiac events (MACE). The secondary end-points: Sudden cardiac death, cardiovascular death, resuscitated cardiac arrest or sustained ventricular tachycardia, device-related complications, and change in quality of life. Course of the study: After a pharmacotherapy is optimized and significant mid-wall myocardial fibrosis excluded, patients will be randomized 1:1 to CRT-P or CRT-D implantation. DISCUSSION: If our hypothesis is confirmed, this could provide evidence for the management of these patients with a significant impact on common daily praxis and health care expenditures. CLINICALTRIALS: gov, NCT04139460.
No takes yet. Share an insight, caveat, or question.
Táborský et al. (2021) conducted an RCT in Non-ischemic dilated cardiomyopathy and heart failure (n=600). Cardiac Resynchronization and Defibrillator Therapy (CRT-D) vs. Cardiac Resynchronization Therapy Pacemaker (CRT-P) was evaluated on Re-hospitalization for heart failure, ventricular tachycardia, major adverse cardiac events (MACE). The CRT-REALITY trial is a planned randomized controlled study designed to evaluate whether CRT-D provides a clinical benefit over CRT-P in patients with non-ischemic heart failure without mid-wall fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: